Moreover, they analyzed NSCLC treated with anti-PD1/PD-L1 antibody monotherapy not including combination therapy with chemotherapy and/or anti-CTLA-4 antibodies, which are the standard treatments for NSCLC, particularly with PD-L1 expression <50% [16]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.